ARCTIC研究:度伐利尤单抗联合或不联合替西木单抗作为转移性非小细胞肺癌三线或后线治疗的III期随机研究
A研究中度伐利尤单抗较标准治疗显著改善OS(11.7 vs 6.8个月,HR 0.63)。B研究中度伐利尤单抗联合替西木单抗较标准治疗OS有数值改善但未达统计学显著(11.5 vs 8.7个月,HR 0.80,P=0.109)。安全性可控。
要点
- PD-L1 TC≥25%经治mNSCLC:度伐利尤单抗较SoC显著延长OS(HR 0.63)。
- PD-L1 TC<25%经治mNSCLC:度伐利尤单抗联合替西木单抗较SoC的OS无显著差异。
- 度伐利尤单抗治疗相关3/4级不良事件发生率低于SoC(9.7% vs 44.4%)。
核心结论
- 在PD-L1 TC≥25%的经治mNSCLC患者中,度伐利尤单抗较标准治疗显著改善OS和PFS。
- 在PD-L1 TC<25%的经治mNSCLC患者中,度伐利尤单抗联合替西木单抗较标准治疗仅显示OS和PFS的数值改善,未达统计学显著。
- 两种免疫治疗方案的安全性特征与既往研究一致。
研究设计与样本
- ARCTIC为III期、随机、开放标签研究,包含两个独立子研究。
- A研究纳入126例PD-L1 TC≥25%的mNSCLC患者,按1:1随机接受度伐利尤单抗或标准治疗。
- B研究纳入469例PD-L1 TC<25%的mNSCLC患者,按3:2:2:1随机接受度伐利尤单抗联合替西木单抗、标准治疗、度伐利尤单抗或替西木单抗单药。
- A研究主要终点为度伐利尤单抗对比标准治疗的OS和PFS(描述性分析);B研究主要终点为度伐利尤单抗联合替西木单抗对比标准治疗的OS和PFS。
主要发现
- A研究:度伐利尤单抗组中位OS为11.7个月,标准治疗组为6.8个月(HR 0.63,95%CI 0.42-0.93)。
- A研究:度伐利尤单抗组中位PFS为3.8个月,标准治疗组为2.2个月(HR 0.71,95%CI 0.49-1.04)。
- B研究:度伐利尤单抗联合替西木单抗组中位OS为11.5个月,标准治疗组为8.7个月(HR 0.80,95%CI 0.61-1.05;P=0.109)。
- B研究:两组中位PFS均为3.5个月(HR 0.77,95%CI 0.59-1.01;P=0.056)。
- A研究治疗相关3/4级不良事件发生率:度伐利尤单抗组9.7%,标准治疗组44.4%;B研究:度伐利尤单抗联合替西木单抗组22.0%,标准治疗组36.4%。
临床怎么用
- 对于PD-L1 TC≥25%的经治mNSCLC患者,度伐利尤单抗可作为三线或后线治疗选择之一,OS获益具有临床意义。
- 对于PD-L1 TC<25%的经治mNSCLC患者,度伐利尤单抗联合替西木单抗未显示显著OS获益,需个体化评估。
- 度伐利尤单抗单药或联合替西木单抗的安全性均优于标准治疗,需关注免疫相关不良事件。
局限性
- A研究为描述性分析,未设正式统计学检验。
- B研究中联合治疗组对比标准治疗的OS和PFS均未达到预设统计学显著性。
- 研究纳入的是经多线治疗的患者,结果外推至更早线治疗需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many patients with metastatic non-small-cell lung cancer (mNSCLC) experience disease progression after first- and second-line treatment; more treatment options are required for these patients. ARCTIC, a phase III, randomized, open-label study, assessed durvalumab ± tremelimumab versus standard of care (SoC) as ≥ third-line treatment of mNSCLC. PATIENTS AND METHODS: ARCTIC comprised two independent sub-studies. Study A: 126 patients with ≥25% of tumor cells (TCs) expressing programmed cell death ligand-1 (PD-L1) were randomized (1 : 1) to durvalumab [up to 12 months 10 mg/kg every 2 weeks (q2w)] or SoC. Study B: 469 patients with PD-L1 TC <25% were randomized (3 : 2 : 2 : 1) to durvalumab + tremelimumab (12 weeks durvalumab 20 mg/kg + tremelimumab 1 mg/kg q4w then 34 weeks durvalumab 10 mg/kg q2w), SoC, durvalumab (up to 12 months 10 mg/kg q2w), or tremelimumab (24 weeks 10 mg/kg q4w then 24 weeks q12w). Primary end points: overall survival (OS) and progression-free survival (PFS) for durvalumab versus SoC (study A; descriptive only) and durvalumab + tremelimumab versus SoC (study B). RESULTS: Study A: median OS 11.7 (durvalumab) versus 6.8 (SoC) months {hazard ratio (HR) 0.63 [95% confidence interval (CI), 0.42-0.93]}; median PFS 3.8 (durvalumab) versus 2.2 (SoC) months [HR 0.71 (95% CI, 0.49-1.04)]. Study B: median OS 11.5 (durvalumab + tremelimumab) versus 8.7 (SoC) months [HR 0.80 (95% CI, 0.61-1.05); P = 0.109]. Median PFS of 3.5 months for both groups [HR 0.77 (95% CI, 0.59-1.01); P = 0.056]. Treatment-related grade 3/4 adverse events: 9.7% (durvalumab) and 44.4% (SoC; study A) and 22.0% (durvalumab + tremelimumab) and 36.4% (SoC; study B). CONCLUSIONS: In heavily pretreated patients with mNSCLC, durvalumab demonstrated clinically meaningful improvements in OS and PFS versus SoC (patients with PD-L1 TC ≥25%); numerical improvements in OS and PFS for durvalumab + tremelimumab versus SoC were observed (patients with PD-L1 TC <25%). Safety profiles were consistent with previous studies. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02352948.
引用
- Planchard D, Reinmuth N, Orlov S, et al. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. Ann Oncol. 2020. PMID: 32201234. doi:10.1016/j.annonc.2020.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。